Comparison Of The Short-term Therapeutic Efficacy Between Ranibizumab And Conbercept For Wet Age-related Macular Degeneration

Objective:To observe and compare the Short-Term therapeutic efficacy of ranibizumab with conbercept for Wet Age-Related Macular Degeneration,and provide the best clinical drug for clinician.Methods:It was a prospective and comparative study.The diagnosed wet age related macular degeneration(wAMD)patients(totally 58)who were treated with treated with intravitreal ranibizumab or conbercept on a monthly treatment regimen from January 2015 to February 2017 in the Subsidiary First Hospital were included in the study.According to the different injection drugs,we set up two treatment groups.Group R,30 patients received intravitreal ranibizumab injections(0.05mg/0.05ml);Group C,28 patients received intravitreal conbercept(0.05mg/0.05ml).Using an on-demand regimen to cure.Age,gender,previous history,intraocular pressure(IOP),best-corrected visual acuity(BCVA),FFA or ICGA or central macular thickness(CMT)that detected by examination of visual acuity and optical coherence tomography(OCT)were collected.The changes of two groups BCVA,CMT,IOP and the injection numbers were recorded during follow-up period.SPSS 22.0 is used to analysis two groups’ dates.Probability less than 0.05 was considered to be statistically significant.Result:Fifty-eight patients were included in the study,groups R,16(16 eyes)from males and 14(14eyes)from females;groups C,11(11 eyes)from males and 17(17eyes)from females.In groups R,compared with the baseline mean BCVA(LogMAR)(0.92±0.47),1w(0.81±0.40),1mo(0.75±0.42),2mo(0.71±0.43),3mo(0.65±0.40),were significantly improved(P<0.05 for both groups);compared with the baseline mean CMT(503.63±188.64)μm,1w(435.47 ± 179.93)μm,Imo(429.93 ± 199.11)μm,2mo(411.27 ± 180.21)μm,3mo(387.80 ± 164.84)μm,were significantly improved(P<0.05 for both groups);compared with the baseline mean IOP(mmHg)(16.37±2.82),1w(15.90±3.00),1mo(15.53±2.62),2mo(15.00±2.18),3mo(15.27±2.80),there was not a significant difference(P>0.05 for both groups).In groups C,compared with the baseline mean BCVA(LogMAR)(0.96±0.48),1w(0.89±0.42),1mo(0.84±0.43),2mo(0.77±0.38),3mo(0.73±0.38),were significantly improved(P<0.05 for both groups);compared with the baseline mean CMT(432.29±241.68)μm,1w(377.04±193.95)μm,1mo(332.39±188.65)μm,2mo(328.75±191.76)μm,3mo(328.14±201.55)μm,were significantly improved(P<0.05 for both groups);compared with the baseline mean IOP(mmHg)(16.04±2.38),1w(16.29±2.19),1mo(15.89±2.27),2mo(16.00±2.28),3mo(15.79±2.77),there was not a significant difference(P>0.05 for both groups).In group R and C,the median BCVA were 0.81±0.40 and 0.89±0.42(P=0.458),the CMT were(435.47± 179.93)μm and(377.04± 193.95)μm(P=0.239)at 1w;the median BCVA were 0.75±0.42 and 0.84±0.43(P=0.425),the CMT were(429.93± 199.11)pm and(332.39± 188.65)μm(P=0.061)at 1 month;the median BCVA were 0.71±0.43 and 0.77±0.38(P=0.585),the CMT were(411.27± 180.21)μm and(328.75 ± 191.76)μm(P=0.097)at 2 month;the median BCVA were(0.65±0.40)and(0.73μ0.38)(P=0.475),the CMT were(387.80±164.84μm and(328.14 ± 201.55)μm(P= 0.221)at 3 month.During the follow-up time,.the change of BCVA and CMT was not significantly different between the two groups(P>0.05 for all).During the follow-up time,In group R and C,the injection numbers were(2.83±0.38)and(2.43±0.50)(P=0.001),it was significantly different between the two groups(P<0.05).Conclusion:1.Ranibizumab group and Conbercopt group both had effective on treatment of wet age-related macular degeneration.2.Ranibizumab group and Conbercopt group were no significant differences on treatment of wet age-related macular degeneration,but Conbercopt group need the less number of injections.